Search Results - "Giustarini, G"

  • Showing 1 - 16 results of 16
Refine Results
  1. 1

    Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis by Antonioli, L., El-Tayeb, A., Pellegrini, C., Fornai, M., Awwad, O., Giustarini, G., Natale, G., Ryskalin, L., Németh, Z. H., Müller, C. E., Blandizzi, C., Colucci, R.

    Published in Purinergic signalling (01-03-2018)
    “…Adenosine represents a powerful modulating factor, which has been shown to orchestrate the scope, duration, and remission of the inflammatory response through…”
    Get full text
    Journal Article
  2. 2

    Role of the A2B receptor–adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats by Antonioli, L, Fornai, M, Awwad, O, Giustarini, G, Pellegrini, C, Tuccori, M, Caputi, V, Qesari, M, Castagliuolo, I, Brun, P, Giron, M C, Scarpignato, C, Blandizzi, C, Colucci, R

    Published in British journal of pharmacology (01-03-2014)
    “…Background and Purpose Adenosine A2B receptors regulate several physiological enteric functions. However, their role in the pathophysiology of intestinal…”
    Get full text
    Journal Article
  3. 3

    Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats by Antonioli, L, Fornai, M, Awwad, O, Giustarini, G, Pellegrini, C, Tuccori, M, Caputi, V, Qesari, M, Castagliuolo, I, Brun, P, Giron, M C, Scarpignato, C, Blandizzi, C, Colucci, R

    Published in British journal of pharmacology (01-03-2014)
    “…Adenosine A(2B) receptors regulate several physiological enteric functions. However, their role in the pathophysiology of intestinal dysmotility associated…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Thalidomide plus Monthly High-dose Dexamethasone in Chemorefractory Myeloma. Results of a Phase II Clinical Study by Bernardeschi, P, Giustarini, G, Montenora, I, Turrisi, G, Dentico, P, Rossi, S, Turano, E, Fiorentini, G

    Published in In vivo (Athens) (01-11-2006)
    “…Thalidomide is a potent anti-myeloma drug which can produce up to a 30-50% overall response rate (ORR) in pre-treated, chemorefractory multiple myeloma. Most…”
    Get full text
    Journal Article
  6. 6

    Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma by Bemardeschi, P, Dentico, P, Rossi, S, Fiorentini, G, Giustarini, G, Turano, E

    “…Thalidomide is active both as single agent and in combination-therapy against refractory or relapsing multiple myeloma. Eigth patients previously treated were…”
    Get more information
    Journal Article
  7. 7

    Chemoresistant Myeloma: Phase II Clinical Study with Low-Dose Thalidomide Plus High-Dose Dexamethasone by Bernardeschi, P., Dentico, P., Rossi, S., Fiorentini, G., Giustarini, G., Montenora, I., Turano, E.

    Published in Journal of chemotherapy (Florence) (01-11-2004)
    “…Thalidomide produces a response rate from 32 to 66% of pre-treated myeloma patients with doses ranging from 100 to 800 mg/daily. Common, dose-related side…”
    Get full text
    Journal Article
  8. 8

    Thyroid metastases from colon cancer case report in a long term survivor by Rossi, S, Fiorentini, G, Porcu, G, Dentico, P, Giustarini, G, Bernardeschi, P

    “…Colon cancer usually has an hematogenous spread to liver and lung: rarely, or in the case of most advanced disease, also brain and bone can be involved…”
    Get more information
    Journal Article
  9. 9
  10. 10

    Role of the A 2B receptor–adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats by Antonioli, L, Fornai, M, Awwad, O, Giustarini, G, Pellegrini, C, Tuccori, M, Caputi, V, Qesari, M, Castagliuolo, I, Brun, P, Giron, M C, Scarpignato, C, Blandizzi, C, Colucci, R

    Published in British journal of pharmacology (01-03-2014)
    “…Background and Purpose Adenosine A 2B receptors regulate several physiological enteric functions. However, their role in the pathophysiology of intestinal…”
    Get full text
    Journal Article
  11. 11

    Anti-inflammatory effect of a novel locally acting A 2A receptor agonist in a rat model of oxazolone-induced colitis by Antonioli, L, El-Tayeb, A, Pellegrini, C, Fornai, M, Awwad, O, Giustarini, G, Natale, G, Ryskalin, L, Németh, Z H, Müller, C E, Blandizzi, C, Colucci, R

    Published in Purinergic signalling (01-03-2018)
    “…Adenosine represents a powerful modulating factor, which has been shown to orchestrate the scope, duration, and remission of the inflammatory response through…”
    Get full text
    Journal Article
  12. 12

    Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs by MESSORI, A, LONGO, G, MORFINI, M, CINOTTI, S, FILIMBERTI, E, GIUSTARINI, G, ROSSI FERRINI, P

    Published in European journal of clinical pharmacology (01-01-1988)
    “…The pharmacokinetics of Factor VIII was evaluated by mathematical modeling in a large-scale study in 62 haemophilia-A subjects, in whom 137 plasma Factor…”
    Get full text
    Journal Article
  13. 13

    Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations by Longo, G, Messori, A, Morfini, M, Baudo, F, Ciavarella, N, Cinotti, S, Filimberti, E, Giustarini, G, Molinari, A C, Ferrini, P R

    Published in American journal of hematology (01-03-1989)
    “…The pharmacokinetics of factor VIII were studied in a series of 20 hemophilia-A patients undergoing surgery. Regardless of the type of operation, elimination…”
    Get more information
    Journal Article
  14. 14

    Single-dose pharmacokinetics of factor IX evaluated by model-independent methods by Longo, G, Cinotti, S, Filimberti, E, Giustarini, G, Messori, A, Morfini, M, Ferrini, P R

    Published in European journal of haematology (01-11-1987)
    “…We studied the pharmacokinetic data of 13 subjects with hemophilia B treated with a single-dose of a Factor IX concentrate (Bebulin TIM2, N = 9; Preconativ, N…”
    Get more information
    Journal Article
  15. 15

    Cancerous colonic polyps by Manetti, R, Biagini, M, Giustarini, G

    Published in Minerva chirurgica (01-11-1996)
    “…The treatment of cancerous polyps of the colon has not been definitely established. In the present study the authors have brought forth their contribution on…”
    Get more information
    Journal Article
  16. 16

    Low risk of transmission of the human immunodeficiency virus by a solvent-detergent-treated commercial factor VIII concentrate by Di Paolantonio, T, Mariani, G, Ghirardini, A, Gringeri, A, Mannucci, P M, Mastrullo, L, De Biasi, R, Giustarini, G, Morfini, M, Schiavoni, M

    Published in Journal of medical virology (01-02-1992)
    “…A study evaluating the risk of a commercial factor VIII (FVIII) concentrate's transmitting the human immunodeficiency virus (HIV) was carried out on…”
    Get more information
    Journal Article